Patents by Inventor Wolfgang Fraunhofer

Wolfgang Fraunhofer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20150023977
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Applicant: ABBVIE INC.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY FORMULATIONS
    Publication number: 20140377275
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 25, 2014
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick, Susan K. Paulson, Tong Zhu
  • Protein formulations and methods of making same
    Patent number: 8883146
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • High concentration anti-TNF? antibody liquid formulations
    Patent number: 8821865
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: September 2, 2014
    Assignee: Abbvie Biotechnology Ltd.
    Inventors: Michael Neu, Markus Tschoepe, Carsten Weber, Wolfgang Fraunhofer, Laura Redden, Martin Gastens, Alexander Feick
  • Crystalline anti-hTNFalpha antibodies
    Patent number: 8772458
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 8, 2014
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Anette Koenigsdorfer, Stefan Gottschalk, Hans-Juergen Krause, Gerhard Winter, David W. Borhani, Wolfgang Fraunhofer
  • Compositions and methods for crystallizing antibodies
    Patent number: 8753839
    Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: June 17, 2014
    Assignee: Abbvie Inc.
    Inventors: Wolfgang Fraunhofer, David W. Borhani, Gerhard Winter, Stefan Gottschalk
  • STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES
    Publication number: 20140141008
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES
    Publication number: 20140141007
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 22, 2014
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu
  • CRYSTALLINE ANTI-HUMAN IL-12 ANTIBODIES
    Publication number: 20140017256
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 16, 2014
    Applicant: ABBVIE INC.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Protein Formulations and Methods of Making Same
    Publication number: 20130156760
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: February 22, 2013
    Publication date: June 20, 2013
    Applicant: ABBVIE, INC.
    Inventors: Wolfgang FRAUNHOFER, Annika BARTL, Hans-juergen KRAUSE, Markus TSCHOEPE, Katharina KALETA
  • Crystalline anti-hTNFalpha antibodies
    Patent number: 8436149
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: May 7, 2013
    Assignee: AbbVie Biotechnology Ltd
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Antibody formulations and methods of making same
    Patent number: 8420081
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: April 16, 2013
    Assignee: AbbVie, Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Crystalline anti-human IL-12 antibodies
    Patent number: 8404819
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: March 26, 2013
    Assignee: AbbVie Inc.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • HIGH CONCENTRATION ANTI-TNFalpha ANTIBODY LIQUID FORMULATIONS
    Publication number: 20120263731
    Abstract: The invention provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, which reduces pain associated with injection in a subject by at least about 50% when compared to injecting an otherwise identical formulation comprising at least one salt and/or at least one buffer. The invention also provides a liquid aqueous pharmaceutical formulation comprising a human anti-TNFa antibody, or antigen-binding portion thereof, having increased bioavailability upon subcutaneous administration into a subject. The formulation may comprise a therapeutic protein, such as a human anti-TNF-alpha antibody, or an antigen-binding portion thereof, or a biosimilar thereof.
    Type: Application
    Filed: November 11, 2011
    Publication date: October 18, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Wolfgang Fraunhofer, Laura Redden, Susan K. Paulson, Tong Zhu, Michael Neu, Markus Tschoepe, Carsten Weber, Martin Gastens, Alexander Feick
  • Crystalline anti-hTNFalpha antibodies
    Publication number: 20120251550
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Application
    Filed: September 2, 2011
    Publication date: October 4, 2012
    Applicant: Abbott Biotechnology Ltd.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • CRYSTALLINE ANTI-HUMAN IL-12 ANTIBODIES
    Publication number: 20120177704
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Application
    Filed: February 14, 2012
    Publication date: July 12, 2012
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • Crystalline anti-human IL-12 antibodies
    Patent number: 8168760
    Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: May 1, 2012
    Assignee: Abbott Laboratories
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY COMPOSITIONS
    Publication number: 20110256135
    Abstract: The present invention relates to stable compositions of anti-NGF antibodies, and antigen-binding fragments thereof, and their uses in the prevention and/or treatment of various diseases and disorders in which NGF activity is detrimental, e.g., pain disorders.
    Type: Application
    Filed: March 16, 2011
    Publication date: October 20, 2011
    Inventors: Wolfgang FRAUNHOFER, Ravi Chari, Vineet Kumar, Rainer Saedler, Michael Siedler, William B. Stine, Carsten Weber
  • Crystalline anti-hTNFalpha antibodies
    Patent number: 8034906
    Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: October 11, 2011
    Assignee: Abbott Biotechnology Ltd.
    Inventors: David W. Borhani, Wolfgang Fraunhofer, Hans-Juergen Krause, Anette Koenigsdorfer, Gerhard Winter, Stefan Gottschalk
  • STABLE HIGH PROTEIN CONCENTRATION FORMULATIONS OF HUMAN ANTI-TNF-ALPHA-ANTIBODIES
    Publication number: 20100278822
    Abstract: The invention provides a liquid pharmaceutical formulation which does not include NaCl and comprises more than 20 mg of a polyol and at least about 100 mg/mL of a human anti-TNF-alpha antibody, or antigen-binding portion thereof. The invention provides a high concentration antibody formulation having long-term stability and advantageous characteristics for subcutaneous administration.
    Type: Application
    Filed: May 3, 2010
    Publication date: November 4, 2010
    Applicant: ABBOTT BIOTECHNOLOGY, LTD.
    Inventors: Wolfgang Fraunhofer, Hans-Juergen Krause, Michael Neu